Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Licofelone Enhances the Efficacy of Paclitaxel in Ovarian Cancer by Reversing Drug Resistance and Tumor Stem-like Properties.

Hirst J, Pathak HB, Hyter S, Pessetto ZY, Ly T, Graw S, Koestler DC, Krieg AJ, Roby KF, Godwin AK.

Cancer Res. 2018 Aug 1;78(15):4370-4385. doi: 10.1158/0008-5472.CAN-17-3993. Epub 2018 Jun 11.

PMID:
29891506
2.

A three-dimensional microenvironment alters protein expression and chemosensitivity of epithelial ovarian cancer cells in vitro.

Lee JM, Mhawech-Fauceglia P, Lee N, Parsanian LC, Lin YG, Gayther SA, Lawrenson K.

Lab Invest. 2013 May;93(5):528-42. doi: 10.1038/labinvest.2013.41. Epub 2013 Mar 4.

3.

Ovarian cancer spheroid cells with stem cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia-resistant metabolism.

Liao J, Qian F, Tchabo N, Mhawech-Fauceglia P, Beck A, Qian Z, Wang X, Huss WJ, Lele SB, Morrison CD, Odunsi K.

PLoS One. 2014 Jan 7;9(1):e84941. doi: 10.1371/journal.pone.0084941. eCollection 2014.

4.
5.

Comparative Study of Multicellular Tumor Spheroid Formation Methods and Implications for Drug Screening.

Gencoglu MF, Barney LE, Hall CL, Brooks EA, Schwartz AD, Corbett DC, Stevens KR, Peyton SR.

ACS Biomater Sci Eng. 2018 Feb 12;4(2):410-420. doi: 10.1021/acsbiomaterials.7b00069. Epub 2017 Mar 13.

6.

3D high-content screening for the identification of compounds that target cells in dormant tumor spheroid regions.

Wenzel C, Riefke B, Gründemann S, Krebs A, Christian S, Prinz F, Osterland M, Golfier S, Räse S, Ansari N, Esner M, Bickle M, Pampaloni F, Mattheyer C, Stelzer EH, Parczyk K, Prechtl S, Steigemann P.

Exp Cell Res. 2014 Apr 15;323(1):131-43. doi: 10.1016/j.yexcr.2014.01.017. Epub 2014 Jan 27.

7.

Comparison of 2D- and 3D-culture models as drug-testing platforms in breast cancer.

Imamura Y, Mukohara T, Shimono Y, Funakoshi Y, Chayahara N, Toyoda M, Kiyota N, Takao S, Kono S, Nakatsura T, Minami H.

Oncol Rep. 2015 Apr;33(4):1837-43. doi: 10.3892/or.2015.3767. Epub 2015 Jan 29.

PMID:
25634491
8.

In-depth phenotypic characterization of multicellular tumor spheroids: Effects of 5-Fluorouracil.

Virgone-Carlotta A, Lemasson M, Mertani HC, Diaz JJ, Monnier S, Dehoux T, Delanoë-Ayari H, Rivière C, Rieu JP.

PLoS One. 2017 Nov 15;12(11):e0188100. doi: 10.1371/journal.pone.0188100. eCollection 2017.

9.

Preclinical activity of the liposomal cisplatin lipoplatin in ovarian cancer.

Casagrande N, Celegato M, Borghese C, Mongiat M, Colombatti A, Aldinucci D.

Clin Cancer Res. 2014 Nov 1;20(21):5496-506. doi: 10.1158/1078-0432.CCR-14-0713. Epub 2014 Sep 17.

10.

Crucial role of HMGA1 in the self-renewal and drug resistance of ovarian cancer stem cells.

Kim DK, Seo EJ, Choi EJ, Lee SI, Kwon YW, Jang IH, Kim SC, Kim KH, Suh DS, Seong-Jang K, Lee SC, Kim JH.

Exp Mol Med. 2016 Aug 26;48:e255. doi: 10.1038/emm.2016.73.

11.

Formation of stable small cell number three-dimensional ovarian cancer spheroids using hanging drop arrays for preclinical drug sensitivity assays.

Raghavan S, Ward MR, Rowley KR, Wold RM, Takayama S, Buckanovich RJ, Mehta G.

Gynecol Oncol. 2015 Jul;138(1):181-9. doi: 10.1016/j.ygyno.2015.04.014. Epub 2015 Apr 22.

12.

Paclitaxel resistance and multicellular spheroid formation are induced by kallikrein-related peptidase 4 in serous ovarian cancer cells in an ascites mimicking microenvironment.

Dong Y, Stephens C, Walpole C, Swedberg JE, Boyle GM, Parsons PG, McGuckin MA, Harris JM, Clements JA.

PLoS One. 2013;8(2):e57056. doi: 10.1371/journal.pone.0057056. Epub 2013 Feb 25.

13.
14.

Induction of hypoxia and necrosis in multicellular tumor spheroids is associated with resistance to chemotherapy treatment.

Däster S, Amatruda N, Calabrese D, Ivanek R, Turrini E, Droeser RA, Zajac P, Fimognari C, Spagnoli GC, Iezzi G, Mele V, Muraro MG.

Oncotarget. 2017 Jan 3;8(1):1725-1736. doi: 10.18632/oncotarget.13857.

15.

Developing multi-cellular tumor spheroid model (MCTS) in the chitosan/collagen/alginate (CCA) fibrous scaffold for anticancer drug screening.

Wang JZ, Zhu YX, Ma HC, Chen SN, Chao JY, Ruan WD, Wang D, Du FG, Meng YZ.

Mater Sci Eng C Mater Biol Appl. 2016 May;62:215-25. doi: 10.1016/j.msec.2016.01.045. Epub 2016 Jan 21.

PMID:
26952417
16.
17.

Evaluation of characteristics of CD44+CD117+ ovarian cancer stem cells in three dimensional basement membrane extract scaffold versus two dimensional monocultures.

Chen J, Wang J, Chen D, Yang J, Yang C, Zhang Y, Zhang H, Dou J.

BMC Cell Biol. 2013 Jan 31;14:7. doi: 10.1186/1471-2121-14-7.

18.

Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden.

Abubaker K, Luwor RB, Zhu H, McNally O, Quinn MA, Burns CJ, Thompson EW, Findlay JK, Ahmed N.

BMC Cancer. 2014 May 6;14:317. doi: 10.1186/1471-2407-14-317.

19.

KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells.

Kim KH, Xie Y, Tytler EM, Woessner R, Mor G, Alvero AB.

J Transl Med. 2009 Jul 20;7:63. doi: 10.1186/1479-5876-7-63.

20.

Chemoprevention of colon and small intestinal tumorigenesis in APC(Min/+) mice by licofelone, a novel dual 5-LOX/COX inhibitor: potential implications for human colon cancer prevention.

Mohammed A, Janakiram NB, Li Q, Choi CI, Zhang Y, Steele VE, Rao CV.

Cancer Prev Res (Phila). 2011 Dec;4(12):2015-26. doi: 10.1158/1940-6207.CAPR-11-0233. Epub 2011 Sep 1.

Supplemental Content

Support Center